A triple immunotherapy regimen combining ipilimumab with atezolizumab and bevacizumab failed to improve outcomes for patients with unresectable hepatocellular carcinoma (HCC), according to phase 2 results from the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial published in The Lancet Gastroenterology & Hepatology. Researchers found the combination increased toxicity without providing a clinically meaningful benefit over the standard doublet therapy.
Why the Triple Therapy Failed to Advance
The trial, which enrolled 229 patients across 36 French hospitals, was designed to see if adding low-dose ipilimumab to the standard atezolizumab-bevacizumab treatment could boost objective response rates. To proceed to phase 3, the study required at least 35 patients in the experimental arm to achieve a complete or partial response within 24 weeks.
According to the findings, 34 patients (30%) in the triple-therapy group reached this threshold, narrowly missing the target. In contrast, 31 patients (27%) treated with the standard doublet of atezolizumab and bevacizumab achieved a response. Because the predefined efficacy target was not met, investigators halted the trial, concluding that the triple combination does not support a new first-line standard for unresectable HCC.
Hepatocellular carcinoma is the most common form of primary liver cancer. Because it is frequently diagnosed at an advanced stage, identifying effective systemic therapies remains a top priority for clinical researchers worldwide.
Toxicity Concerns in Triple Immunotherapy
The addition of ipilimumab resulted in a higher burden of serious adverse events compared to the doublet regimen. Data from the trial show that 55 patients (49%) receiving the triple combination experienced serious adverse events, compared to 48 patients (42%) in the control group.
Most concerning were the treatment-related deaths reported in the experimental arm. Six patients (5%) receiving the triple therapy died due to treatment-related adverse events, while no such deaths occurred in the doublet group. Investigators identified arterial hypertension, asthenia, colitis, and confusional syndrome as the most frequent grade 3-4 treatment-related adverse events.
Clinical Implications for HCC Management
For healthcare professionals, the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial serves as a reminder that intensifying immunotherapy regimens does not always translate to better patient survival or tumor control. The findings suggest that the current standard of care—atezolizumab plus bevacizumab—remains the preferred path for eligible patients with unresectable HCC.
When evaluating new combination therapies in oncology, clinicians should weigh the potential for incremental response gains against the established safety profiles of existing first-line treatments, especially given the increased risk of severe toxicity in triple-regimen trials.
Frequently Asked Questions
- What is the standard first-line treatment for unresectable HCC?
Current clinical practice often relies on the combination of atezolizumab and bevacizumab for patients with unresectable hepatocellular carcinoma. - Why was the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial stopped?
The trial did not meet its predefined efficacy threshold of 35 responders in the experimental arm, and the addition of ipilimumab increased serious toxicity. - Were there deaths associated with the triple-therapy regimen?
Yes, the study reported six treatment-related deaths (5%) in the triple-therapy group, compared to zero in the doublet-therapy group.
For more updates on the latest clinical trials and oncology research, subscribe to our newsletter or explore our archive of cancer treatment reports.
Worth a look